These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9041207)

  • 1. Iron management in end-stage renal disease.
    Fishbane S; Maesaka JK
    Am J Kidney Dis; 1997 Mar; 29(3):319-33. PubMed ID: 9041207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin.
    Gallieni M
    Int J Artif Organs; 1998 Nov; 21(11):681-6. PubMed ID: 9894741
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
    Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
    Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients.
    Peacock E; Lindenfeld SM
    ANNA J; 1999 Jun; 26(3):337-43. PubMed ID: 10633605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
    Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
    Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients.
    Tsuchiya K; Okano H; Teramura M; Iwamoto Y; Yamashita N; Suda A; Shimada K; Nihei H; Ando M
    Clin Nephrol; 2003 Feb; 59(2):115-23. PubMed ID: 12608554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron deficiency in patients with renal failure.
    Nissenson AR; Strobos J
    Kidney Int Suppl; 1999 Mar; 69():S18-21. PubMed ID: 10084282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease.
    Hutchinson FN; Jones WJ
    Am J Kidney Dis; 1997 May; 29(5):651-7. PubMed ID: 9159297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond.
    Mittman N
    Am J Kidney Dis; 1999 Jul; 34(1):173-6. PubMed ID: 10401035
    [No Abstract]   [Full Text] [Related]  

  • 14. [Stability of hemoglobin levels: an indispensible paradigm change in medical management].
    Zaoui P; Deray G; Ortiz JP; Rostaing L
    Nephrol Ther; 2011 Feb; 7(1 Suppl 2):H5-7. PubMed ID: 21371678
    [No Abstract]   [Full Text] [Related]  

  • 15. Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines.
    Fishbane S
    Semin Dial; 2008; 21(3):217-20. PubMed ID: 18248518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients.
    Fishbane S; Lynn RI
    Am J Kidney Dis; 1995 Mar; 25(3):426-32. PubMed ID: 7872320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron for the treatment of predialysis anemia.
    Silverberg DS; Blum M; Agbaria Z; Schwartz D; Zubkov A; Yachnin T; Iaina A
    Kidney Int Suppl; 1999 Mar; 69():S79-85. PubMed ID: 10084291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
    Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
    Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of reticulocyte hemoglobin equivalent with traditional markers of iron and erythropoiesis in pediatric dialysis.
    Davidkova S; Prestidge TD; Reed PW; Kara T; Wong W; Prestidge C
    Pediatr Nephrol; 2016 May; 31(5):819-26. PubMed ID: 26667237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
    Trivedi HS; Brooks BJ
    Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.